The ASHP Foundation today announced the appointment of Christopher A. Hatwig, R.Ph., M.S., FASHP, President of Apexus, LLC, to the ASHP Foundation Board of Directors as a Director at Large.

Mr. Hatwig is one of the nation’s foremost experts on the 340B Drug Pricing Program. He has an exceptional record of leading innovative and progressive pharmacy services in acute and ambulatory care settings. As president of Apexus, a mission-driven organization that provides innovative pharmacy solutions for the safety net community, he oversees the company’s role as the 340B Prime Vendor for the Health Resources and Services Administration’s (HRSA’s) 340B Drug Pricing Program.

He is the former Director of Ambulatory Pharmacy Services and Value Analysis Programs at Parkland Health & Hospital System in Dallas, where he managed one of the nation’s largest and more progressive ambulatory pharmacy programs serving low-income and uninsured patients.

“The ASHP Foundation is fortunate to have Chris’s unique perspective and expertise on our Board of Directors,” said ASHP Foundation Chair Jack Tighe. “We look forward to working with Chris as the Foundation continues to evolve in its efforts to support ASHP and its members.”

A 2018 recipient of the ASHP Board of Directors Distinguished Leadership Award, Mr. Hatwig served as Chair of the ASHP Council on Administrative Affairs and is a reviewer for AJHP.

Mr. Hatwig earned his bachelor's degree in Pharmacy from the University of Arkansas. He completed residencies in hospital pharmacy and hospital pharmacy administration at the University of Wisconsin, and received his master’s degree in Hospital Pharmacy.


Learn more about the Prime Vendor Program and how Apexus supports 340B.

Learn More